215 citations,
November 2006 in “Journal of The American Academy of Dermatology” Dutasteride more effective for hair growth, but has more side effects than finasteride.
72 citations,
April 2008 in “The Journal of urology/The journal of urology” Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
56 citations,
April 1998 in “Steroids” Finasteride reduces hair loss and treats BPH without major hormone changes, but may cause sexual dysfunction.
46 citations,
October 1999 in “Journal of The American Academy of Dermatology” Finasteride effectively treats male pattern hair loss with a 1 mg daily dose.
32 citations,
April 1999 in “Expert Opinion on Investigational Drugs” Finasteride effectively treats male hair loss, improving growth and density.
23 citations,
July 1993 in “Pharmacotherapy” Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.
18 citations,
January 2003 in “Gynecological Endocrinology” Low-dose finasteride effectively reduces hirsutism without serious side-effects.
6 citations,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.
71 citations,
January 2004 in “Dermatology” Oral finasteride works better than topical minoxidil for hair growth, both are safe.
51 citations,
October 2002 in “European journal of endocrinology” Low-dose finasteride effectively treats hirsutism, is safe, and cost-effective.
50 citations,
March 2017 in “PeerJ” Using finasteride or dutasteride may cause long-lasting erectile dysfunction.
48 citations,
November 1992 in “Clinical Endocrinology” Long-term finasteride use doesn't change bone density or metabolism.
39 citations,
April 2007 in “Therapeutic Drug Monitoring” Finasteride affects urinary steroid profiles and can potentially hide steroid abuse in sports drug testing.
13 citations,
August 1997 in “Steroids” Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.
10 citations,
October 2010 in “International Journal of Andrology” Finasteride doesn't affect oral testosterone undecanoate, and high DHT levels may cause acne, prostate issues, and hair loss.
1 citations,
July 2017 in “The Journal of Urology” Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.
50 citations,
May 2000 in “Fertility and Sterility” Flutamide reduces hair growth better but has more side effects.
2 citations,
May 2019 in “PubMed” Oral finasteride and dutasteride may negatively affect erectile function in rats.
15 citations,
July 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
15 citations,
December 2006 in “Clinical interventions in aging” 5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.
10 citations,
October 2018 in “Sexual medicine reviews” Men using hair loss drugs like finasteride may experience sexual side effects like erectile dysfunction, but it's unclear who will be affected and when. Treating depression and sexual symptoms is suggested, as these men often have higher rates of both. More research is needed to understand why these side effects occur.
5 citations,
July 1994 in “PubMed” Finasteride, when taken daily, lowers dihydrotestosterone levels but doesn't noticeably affect adrenal steroid production, except by blocking the 5 alpha-reductase enzyme.
March 2023 in “Translational Andrology and Urology” 5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
223 citations,
December 2010 in “The Journal of Sexual Medicine” Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.
408 citations,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
57 citations,
July 2016 in “The Journal of Sexual Medicine” 5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
44 citations,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
35 citations,
April 2013 in “Sexual medicine reviews” 5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.
33 citations,
January 2016 in “Skin appendage disorders” The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.
31 citations,
September 2008 in “International Journal of Andrology” 5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.